Atezolizumab in a CoHort of pretreated, advanced, non-small cell lung cancer patients with rare HistologiCal SubtypEs (CHANCE trial)

BACKGROUND: Although immunotherapy with immune-checkpoint inhibitors (ICIs) has profoundly changed the therapeutic scenario in the treatment of advanced non-small cell lung cancer (NSCLC), trials of ICIs only enrolled NSCLC patients with common histology. Atezolizumab was approved by the United Stat...

Descripción completa

Detalles Bibliográficos
Autores principales: Gelsomino, Francesco, Lamberti, Giuseppe, Tiseo, Marcello, Rocco, Danilo, Pasello, Giulia, Cecere, Fabiana Letizia, Chella, Antonio, Grilli, Giada, Mandruzzato, Marcella, Tognetto, Michele, Garassino, Marina Chiara, Macerelli, Marianna, Novello, Silvia, Roila, Fausto, Colantonio, Ida, Grossi, Francesco, Fiorentino, Michelangelo, Ardizzoni, Andrea
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7372524/
https://www.ncbi.nlm.nih.gov/pubmed/32733604
http://dx.doi.org/10.1177/1758835920915983

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7372524/
https://www.ncbi.nlm.nih.gov/pubmed/32733604
http://dx.doi.org/10.1177/1758835920915983

Ejemplares similares